Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design

Frontiers in Immunology

Volumn 2, Issue DEC, 2011, Pages

  Kaminski, Denise A ^a   Lee, F Eun Hyung ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antibody; Hemagglutinin; Influenza virus; Matrix 2 external domain; Nucleoprotein; Vaccine

Indexed keywords

EID: 84866309001     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00076     Document Type: Review

References (133)

1. (1989). Oxford English Dictionary. Available at: http://www.oed.com/view/Entry/95531?redirectedFrom=influenza#eid
2. (2011). Review of the 2010-2011 winter influenza season, northern hemisphere. Wkly. Epidemiol. Rec. 86, 222-227. (PMID 21661271).
3. Ahmad, R., Sindhu, S. T., Toma, E., Morisset, R., Vincelette, J., Menezes, J., and Ahmad, A. (2001). Evi dence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21, 227-233.
4. Basler, C. F., and Aguilar, P. V. (2008). Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res. 79, 166-178.
5. Beran, J., Vesikari, T., Wertzova, V., Kar-vonen, A., Honegr, K., Lindblad, N., Van Belle, P., Peeters, M., Innis, B. L., and Devaster, J. M. (2009). Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J. Infect. Dis. 200, 1861-1869.
6. Bergtold, A., Desai, D. D., Gavhane, A., and Clynes, R. (2005). Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23, 503-514.
7. Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C., Lambe, T., Fletcher, H. A., Hill, A. V., and Gilbert, S. C. (2011). Potent CD8+ T-cell immunogenicity in humans of a novel heterosub-typic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52, 1-7.
8. Bodewes,R.,Kreijtz, J. H.,Hillaire, M. L., Geelhoed-Mieras, M. M., Fouchier, R. A., Osterhaus, A. D., and Rim-melzwaan, G. F. (2010). Vaccination with whole inactivated virus vaccine affects the induction of hetero-subtypic immunity against influenza virus A/H5N1 and immunodomi-nance of virus-specific CD8+ T-cell responses in mice. J. Gen. Virol. 91, 1743-1753.
9. Bodewes, R., Kreijtz, J. H., and Rim-melzwaan, G. F. (2009). Yearly influenza vaccinations: a double-edged sword? Lancet. Infect. Dis. 9, 784-788.
10. Brett, I. C., and Johansson, B. E. (2005). Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339, 273-280.
11. Brown, D. M., Dilzer, A. M., Meents, D. L., and Swain, S. L. (2006). CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177, 2888-2898.
12. Carragher, D. M., Kaminski, D. A., Moquin, A., Hartson, L., and Randall, T. D. (2008). A novel role for non-neutralizing antibodies against nucleopro-tein in facilitating resistance to influenza virus. J. Immunol. 181, 4168-4176.
13. Chehadeh, W., Bouzidi, A., Alm, G., Wattre, P., and Hober, D. (2001). Human antibodies isolated from plasma by affinity chromatogra-phy increase the coxsackievirus B4-induced synthesis of interferon-alpha by human peripheral blood mononuclear cells in vitro. J. Gen. Virol. 82, 1899-1907.
14. Corti, D., Suguitan, A. L. Jr., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C., Luke, C. J., Torres-Velez, F. J., Temper-ton, N. J., Weiss, R. A., Sallusto, F., Subbarao, K., and Lanzavecchia, A. (2010). Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673.
15. Corti, D.,Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., Silacci, C., Fernandez-Rodriguez, B. M.,Agatic, G., Bianchi, S., Giacchetto-Sasselli, I., Calder, L., Sallusto, F., Collins, P., Haire, L. F., Temperton, N., Langedijk, J. P., Skehel, J. J., and Lanzavecchia, A. (2011). A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856.
16. Cretescu, L., Beare, A. S., and Schild, G. C. (1978). Formation of antibody to matrix protein in experimental human influenza A virus infections. Infect. Immun. 22, 322-327.
17. Crowe, S. R., Miller, S. C., Shenyo, R. M., and Woodland, D. L. (2005). Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge. J. Immunol. 174, 696-701.
18. Crowe, S. R., Miller, S. C., and Woodland, D. L. (2006). Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24, 452-456.
19. De Filette, M., Ysenbaert, T., Roose, K., Schotsaert, M., Roels, S., Goossens, E., Schepens, B., Fiers, W., and Sae-lens, X. (2011). Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunopro-tective. J. Gen. Virol. 92, 301-306.
20. Dhodapkar, K. M., Krasovsky, J., Williamson, B., and Dhodapkar, M. V. (2002). Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125-133.
21. Du, L., Zhou, Y., and Jiang, S. (2010). Research and development of universal influenza vaccines. Microbes Infect. 12, 280-286.
22. Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., Goudsmit, J., and Wilson, I. A. (2009). Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251.
23. Ekiert, D. C., Friesen, R. H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J., Brandenburg, B., Vogels, R., Brak-enhoff, J. P., Kompier, R., Koldijk, M. H., Cornelissen, L. A., Poon, L. L., Peiris, M., Koudstaal, W., Wilson, I. A., and Goudsmit, J. (2011). A highly conserved neutralizing epi-tope on group 2 influenza A viruses. Science 333, 843-850.
24. El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., and Saelens, X. (2011). Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186, 1022-1031.
25. Ennis, F. A., Yi-Hua, Q., and Schild, G. C. (1982). Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J. Gen. Virol. 58, 273-281.
26. Epstein, S. L., Kong, W. P., Misplon, J. A., Lo, C. Y., Tumpey, T. M., Xu, L., and Nabel, G. J. (2005). Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23, 5404-5410.
27. Epstein, S. L., Lo, C. Y., Misplon, J. A., Lawson, C. M., Hendrick-son, B. A., Max, E. E., and Sub-barao, K. (1997). Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, b2-microglobulin-deficient, and J chain-deficient mice. J. Immunol. 158, 1222-1230.
28. Epstein, S. L., Stack, A., Misplon, J. A., Lo, C. Y., Mostowski, H., Ben-nink, J., and Subbarao, K. (2000). Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int. Immunol. 12, 91-101.
29. Ernst, W. A., Kim, H. J., Tumpey, T. M., Jansen, A. D., Tai, W., Cramer, D. V., Adler-Moore, J. P., and Fujii, G. (2006). Protection against H1,H5,H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24, 5158-5168.
30. Feng, J., Zhang, M., Mozdzanowska, K., Zharikova, D., Hoff, H., Wunner, W., Couch, R. B., and Gerhard, W. (2006). Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 3, 102.
31. Forthal, D. N., Landucci, G., and Daar, E. S. (2001). Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75, 6953-6961.
32. Fraser, C., Donnelly, C. A., Cauchemez, S., Hanage, W. P., Van Kerkhove, M. D., Hollingsworth, T. D., Griffin, J., Baggaley, R. F., Jenkins, H. E., Lyons, E. J., Jombart, T., Hinsley, W. R., Grassly, N. C., Balloux, F., Ghani, A. C., Ferguson, N. M., Rambaut, A., Pybus, O. G., Lopez-Gatell, H., Alpuche-Aranda, C. M., Chapela, I. B., Zavala, E. P., Guevara, D. M., Checchi, F., Garcia, E., Hugonnet, S., Roth, C., and Collaboration, W. H. O. R. P. A. (2009). Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324, 1557-1561.
33. Fu, T. M., Guan, L., Friedman, A., Schofield, T. L., Ulmer, J. B., Liu, M. A., and Donnelly, J. J. (1999). Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J. Immunol. 162, 4163-4170.
34. Gabbard, J., Velappan, N., Di Niro, R., Schmidt, J., Jones, C. A., Tompkins, S. M., and Bradbury, A. R. (2009). A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng. Des. Sel. 22, 189-198.
35. Gamblin, S. J., and Skehel, J. J. (2010). Influenza hemagglutinin and neuraminidase membrane gly-coproteins. J. Biol. Chem. 285, 28403-28409.
36. Gerdil, C. (2003). The annual production cycle for influenza vaccine. Vaccine 21, 1776-1779.
37. Gomez-Roman, V. R., Patterson, L. J., Venzon, D., Liewehr, D., Aldrich, K., Florese, R., and Robert-Guroff, M. (2005). Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174, 2185-2189.
38. Groh, V., Li, Y. Q., Cioca, D., Hunder, N. N., Wang, W., Riddell, S. R., Yee, C., and Spies, T. (2005). Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl. Acad. Sci. U.S.A. 102, 6461-6466.
39. Hale, B. G., Randall, R. E., Ortin, J., and Jackson, D. (2008). The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89, 2359-2376.
40. Halliley, J. L., Kyu, S., Kobie, J. J., Walsh, E. E., Falsey, A. R., Randall, T. D., Treanor, J., Feng, C., Sanz, I., and Lee, F. E. (2010). Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 28, 3582-3587.
41. Han, T., and Marasco, W. A. (2011). Structural basis of influenza virus neutralization. Ann. N. Y. Acad. Sci. 1217, 178-190.
42. Hancock, K., Veguilla, V., Lu, X., Zhong, W., Butler, E. N., Sun, H., Liu, F., Dong, L., DeVos, J. R., Gargiullo, P. M., Brammer, T. L., Cox, N. J., Tumpey, T. M., and Katz, J. M. (2009). Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945-1952.
43. Harbers, S. O., Crocker, A., Cata-lano, G., D'Agati, V., Jung, S., Desai, D. D., and Clynes, R. (2007). Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J. Clin. Invest. 117, 1361-1369.
44. Hensley, S. E., Das, S. R., Bailey, A. L., Schmidt, L. M., Hickman, H. D., Jayaraman, A., Viswanathan, K., Raman, R., Sasisekharan, R., Bennink, J. R., and Yewdell, J. W. (2009). Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326, 734-736.
45. Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E., Beurskens, F. J., Bakker, J. M., Lanigan, C. M., Lan-ducci, G., Forthal, D. N., Parren, P. W., Marx, P. A., and Burton, D. R. (2007). Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104.
46. Hober, D., Chehadeh, W., Bouzidi, A., and Wattre, P. (2001). Antibody-dependent enhancement of coxsack-ievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. J. Infect. Dis. 184, 1098-1108.
47. Hutchinson, E. C., von Kirchbach, J. C., Gog, J. R., and Digard, P. (2010). Genome packaging in influenza A virus. J. Gen. Virol. 91, 313-328.
48. Ito, T.,Gorman,O. T.,Kawaoka,Y.,Bean, W. J., and Webster, R. G. (1991). Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 65, 5491-5498.
49. Itoh, Y., Shinya, K., Kiso, M., Watan-abe, T., Sakoda, Y., Hatta, M., Muramoto, Y. T. D., Sakai-Tagawa, Y., Noda, T., Sakabe, S., Imai, M., Hatta, Y., Watanabe, S., Li, C., Yamada, S., Fujii, K., Murakami, S., Imai, H., Kakugawa, S., Ito, M., Takano, R., Iwatsuki-Horimoto, K., Shimojima, M., Horimoto, T., Goto, H., Takahashi, K., Makino, A., Ishigaki, H., Nakayama, M., Okamatsu, M., Takahashi, K., War-shauer, D., Shult, P. A., Saito, R., Suzuki, H., Furuta,Y.,Yamashita, M., Mitamura, K., Nakano, K., Naka-mura, M., Brockman-Schneider, R., Mitamura, H., Yamazaki, M., Sug-aya, N., Suresh, M., Ozawa, M., Neumann, G., Gern, J., Kida, H., Ogasawara, K., and Kawaoka, Y. (2009). In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460, 1021-1025.
50. Jackson, L. A., Gaglani, M. J., Key-serling, H. L., Balser, J., Bou-veret, N., Fries, L., and Tre-anor, J. J. (2010). Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect. Dis. 10, 71. doi:10.1186/1471-2334-10-71
51. Jegerlehner, A., Schmitz, N., Storni, T., and Bachmann, M. F. (2004). Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172, 5598-5605.
52. Johansson, B. E., and Kilbourne, E. D. (1993). Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol. 67, 5721-5723.
53. Johansson, B. E., Matthews, J. T., and Kilbourne, E. D. (1998). Supplementation of conventional influenza A vaccine with purified viral neu-raminidase results in a balanced and broadened immune response. Vaccine 16, 1009-1015.
54. Johansson, B. E., Moran, T. M., Bona, C. A., Popple, S. W., and Kilbourne, E. D. (1987). Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemag-glutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139, 2010-2014.
55. Khurana, S., Suguitan, A. L. Jr., Rivera, Y., Simmons, C. P., Lanzavecchia, A., Sallusto, F., Manischewitz, J., King, L. R., Subbarao, K., and Gold-ing, H. (2009). Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6, e1000049. doi:10.1371/jour-nal.pmed.1000049
56. Kim, W. I., Wu, W. H., Janke, B., and Yoon, K. J. (2006). Characterization of the humoral immune response of experimentally infected and vaccinated pigs to swine influenza viral proteins. Arch. Virol. 151, 23-36.
57. Koopmans, M., Wilbrink, B., Conyn, M., Natrop, G., van der Nat, H., Vennema, H., Meijer, A., van Steen-bergen, J., Fouchier, R., Osterhaus, A., and Bosman, A. (2004). Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363, 587-593.
58. Korteweg, C., and Gu, J. (2008). Pathology, molecular biology, and patho-genesis of avian influenza A (H5N1) infection in humans. Am. J. Pathol. 172, 1155-1170.
59. Krause, J. C., Tumpey, T. M., Huffman, C. J., McGraw, P. A., Pearce, M. B., Tsibane, T., Hai, R., Basler, C. F., and Crowe, J. E. Jr. (2010). Naturally occurring human monoclonal antibodies neutralize both [1918] and 2009 pandemic influenza A (H1N1) viruses. J. Virol. 84, 3127-3130.
60. Krejnusova, I., Gocnikova,H., Bystricka, M., Blaskovicova, H., Polakova, K., Yewdell, J., Bennink, J., and Russ, G. (2009). Antibodies to PB1-F2 protein are induced in response to influenza A virus infection. Arch. Virol. 154, 1599-1604.
61. Kuo, R. L., Zhao, C., Malur, M., and Krug, R. M. (2010). Influenza A virus strains that circulate in humans differ in the ability of their NS1 proteins to block the activation of IRF3 and interferon-beta transcription. Virology 408, 146-158.
62. Lamb, R. A., and Lai, C. J. (1981). Conservation of the influenza virus membrane protein (M1) amino acid sequence and an open reading frame of RNAsegment 7encodinga second protein (M2) in H1N1 and H3N2 strains. Virology 112, 746-751.
63. Lamb,R. A., Zebedee,S. L., and Richardson, C. D. (1985). Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40, 627-633.
64. LaMere, M. W., Lam, H. T., Moquin, A., Haynes,L., Lund,F. E., Randall, T. D., and Kaminski, D. A. (2011a). Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186, 4331-4339.
65. LaMere, M. W., Moquin, A., Lee, F. E., Misra, R. S., Blair, P. J., Haynes, L., Randall, T. D., Lund, F. E., and Kaminski, D. A. (2011b). Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85, 5027-5035.
66. Lee, F. E., Halliley, J. L., Walsh, E. E., Moscatiello, A. P., Kmush, B. L., Falsey, A. R., Randall, T. D., Kaminski, D. A., Miller, R. K., and Sanz, I. (2011). Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J. Immunol. 186, 5514-5521.
67. Li, S., and Leader, S. (2007). Economic burden and absenteeism from influenza-like illness in healthy households with children (5-17 years) in the US. Respir. Med. 101, 1244-1250.
68. Liang, S., Mozdzanowska, K., Palladino, G., and Gerhard, W. (1994). Het-erosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152, 1653-1661.
69. Lo, C. Y., Wu, Z., Misplon, J. A., Price, G. E., Pappas, C., Kong, W. P., Tumpey, T. M., and Epstein, S. L. (2008). Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26, 2062-2072.
70. Machy, P., Serre, K., and Leserman, L. (2000). Class I-restricted presentation of exogenous antigen acquired by Fcg-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 30, 848-857.
71. McMichael, A. J., Gotch, F. M., Dong-worth, D. W., Clark,A., and Potter, C. W. (1983). Declining T-cell immunity to influenza, 1977-82. Lancet 2, 762-764.
72. Medina, R. A., and Garcia-Sastre, A. (2011). Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9, 590-603.
73. Misplon, J. A., Lo, C. Y., Gabbard, J. D., Tompkins, S. M., and Epstein, S. L. (2010). Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 28, 5817-5827.
74. Molinari, N. A., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W.,Wortley, P. M.,Weintraub,E.,and Bridges, C. B. (2007). The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25, 5086-5096.
75. Mossad, S. B. (2007). Influenza update 2007-2008: vaccine advances, pandemic preparation. Cleve. Clin. J. Med. 74, 889-894.
76. Mossad, S. B. (2008). 2008-2009 Influenza update: a better vaccine match. Cleve. Clin. J. Med. 75, 865-870.
77. Mozdzanowska, K., Maiese, K., Furchner, M., and Gerhard, W. (1999). Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254, 138-146.
78. Murphy, B. R., Kasel, J. A., and Chanock, R. M. (1972). Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286, 1329-1332.
79. Nabel, G. J., Wei, C. J., and Ledgerwood, J. E. (2011). Vaccinate for the next H2N2 pandemic now. Nature 471, 157-158.
80. Nayak, B., Kumar, S., DiNapoli, J. M., Paldurai, A., Perez, D. R., Collins, P. L., and Samal, S. K. (2010). Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol. 84, 2408-2420.
81. Neirynck, S., Deroo, T., Saelens, X., Van-landschoot, P., Jou, W. M., and Fiers, W. (1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157-1163.
82. Neumann, G., Noda, T., and Kawaoka, Y. (2009). Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459, 931-939.
83. Nguyen, H. H., Zemlin, M., Ivanov, I. I., Andrasi, J., Zemlin, C., Vu, H. L., Schelonka, R., Schroeder, H. W. Jr., and Mestecky, J. (2007). Heterosub-typic immunity to influenza A virus infection requires a properly diversified antibody repertoire. J. Virol. 81, 9331-9338.
84. Nichol, K. L. (2011). Cost-effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 29, 7554-7558.
85. Nichol, K. L., D'Heilly, S. J., Green-berg, M. E., and Ehlinger, E. (2009). Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin. Infect. Dis. 48, 292-298.
86. Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P.,and Hak, E. (2007). Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357, 1373-1381.
87. Oh, H. L., Akerstrom, S., Shen, S., Bereczky, S., Karlberg, H., Klingstrom, J., Lal, S. K., Miraz-imi, A., and Tan, Y. J. (2010). An antibody against a novel and conserved epitope in the hemagglu-tinin 1 subunit neutralizes numerous H5N1 influenza viruses. J. Virol. 84, 8275-8286.
88. Ohmit, S. E., Victor, J. C., Rotthoff, J. R., Teich, E. R., Truscon, R. K., Baum, L. L., Rangarajan, B., Newton, D. W., Boulton, M. L., and Monto, A. S. (2006). Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355, 2513-2522.
89. Okuno, Y., Matsumoto, K., Isegawa, Y., and Ueda, S. (1994). Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 68, 517-520.
90. Palmer, P., Charley, B., Rombaut, B., Daeron, M., and Lebon, P. (2000). Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II Fcγ receptor (CD32). Virology 278, 86-94.
91. Peiris, M., Yuen, K. Y., Leung, C. W., Chan, K. H., Ip, P. L., Lai, R. W., Orr, W. K., and Shortridge, K. F. (1999). Human infection with influenza H9N2. Lancet 354, 916-917.
92. Portela, A., and Digard, P. (2002). The influenza virus nucleoprotein: amultifunctionalRNA-bindingpro-tein pivotal to virus replication. J. Gen. Virol. 83, 723-734.
93. Potter, C. W. (2001). A history of influenza. J. Appl. Microbiol. 91, 572-579.
94. Powers, D. C., Kilbourne, E. D., and Johansson, B. E. (1996). Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin. Diagn. Lab. Immunol. 3, 511-516.
95. Price, G. E., Soboleski, M. R., Lo, C. Y., Misplon, J. A., Pappas, C., Houser, K. V., Tumpey, T. M., and Epstein, S. L. (2009). Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27, 6512-6521.
96. Rangel-Moreno, J., Carragher, D. M., Misra, R. S., Kusser, K., Hartson, L., Moquin, A., Lund, F. E., and Randall, T. D. (2008). B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J. Immunol. 180, 454-463.
97. Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., and Amigorena, S. (1999). Fcγ receptor-mediated induction of dendritic cell maturation and major histocom-patibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380.
98. Rodriguez, A., Regnault, A., Klei-jmeer, M., Ricciardi-Castagnoli, P., and Amigorena, S. (1999). Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1, 362-368.
99. Rossman, J. S., and Lamb, R. A. (2011). Influenza virus assembly and budding. Virology 411, 229-236.
100. Sambhara, S., Kurichh, A., Miranda, R., Tumpey, T., Rowe, T., Renshaw, M., Arpino, R., Tamane, A., Kandil, A., James, O., Underdown, B., Klein, M., Katz, J., and Burt, D. (2001). Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211, 143-153.
101. Sandbulte, M. R., Jimenez, G. S., Boon, A. C., Smith, L. R., Treanor, J. J., and Webby, R. J. (2007). Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unex-posed humans. PLoS Med. 4, e59. doi:10.1371/journal.pmed.0040059
102. Shu, L. L., Bean, W. J., and Webster, R. G. (1993). Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J. Virol. 67, 2723-2729.
103. Skehel, J. J., and Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569.
104. Skountzou, I., Koutsonanos, D. G., Kim, J. H., Powers, R., Satyab-hama, L., Masseoud, F., Weldon, W. C., Martin Mdel, P., Mittler, R. S., Compans, R., and Jacob, J. (2010). Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J. Immunol. 185, 1642-1649.
105. Smith, G. J. D., Vihaykrishna, D., Bahl, J., Lycett, S. J., Worobey, M., Pybus, O. G., Ma, S. K., Cheung, C. L., Raghwani, J., Bhatt, S., Peiris, J. S. M., Guan, Y., and Rambaut, A. (2009). Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza epidemic. Nature 459, 1122-1125.
106. Soboleski, M. R., Gabbard, J. D., Price, G. E., Misplon, J. A., Lo, C. Y., Perez, D. R., Ye, J., Tompkins, S. M., and Epstein, S. L. (2011). Cold-adapted influenza and recom-binant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS ONE 6, e21937. doi:10.1371/jour-nal.pone.0021937
107. Steel, J., Lowen, A. C., Wang, T. T., Yon-dola, M., Gao, Q., Haye, K., Garcia-Sastre, A., and Palese, P. (2010). Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1, e00018-e00010.
108. Stratov, I., Chung, A., and Kent, S. J. (2008). Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J. Virol. 82, 5450-5459.
109. Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L., Santelli, E., Stec, B., Cadwell, G., Ali, M., Wan, H., Murakami, A., Yammanuru, A., Han, T., Cox, N. J., Bankston, L. A., Donis, R. O., Liddington, R. C., and Marasco, W. A. (2009). Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273.
110. Sui, J., Sheehan, J., Hwang, W. C., Bankston, L. A., Burchett, S. K., Huang, C. Y., Liddington, R. C., Beigel, J. H., and Marasco, W. A (2011). Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 52, 1003-1009.
111. Sukeno, N., Otsuki, Y., Konno, J., Yamane, N., Odagiri, T., Arikawa, J., and Ishida, N. (1979). Anti-nucleoprotein antibody response in influenza A infection. Tohoku J. Exp. Med. 128, 241-249.
112. Taubenberger, J. K., and Kash, J. C. (2010). Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7, 440-451.
113. Throsby, M., van den Brink, E., Jon-geneelen, M., Poon, L. L., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., Cinatl, J., ter Meulen, J., Lasters, I., Carsetti, R., Peiris, M., de Kruif, J.,and Goudsmit, J. (2008). Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942. doi:10.1371/journal.pone.0003942
114. Tompkins, S. M., Zhao, Z. S., Lo, C. Y., Misplon, J. A., Liu, T., Ye, Z., Hogan, R. J., Wu, Z., Ben-ton, K. A., Tumpey, T. M., and Epstein, S. L. (2007). Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging Infect. Dis. 13, 426-435.
115. Tosh, P. K., Jacobson, R. M., and Poland, G. A. (2010). Influenza vaccines: from surveillance through production to protection. Mayo Clin. Proc. 85, 257-273.
116. Treanor, J. J., Tierney, E. L., Zebedee, S. L., Lamb, R. A., and Murphy, B R. (1990). Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64, 1375-1377.
117. Tsuchiya, E., Sugawara, K., Hongo, S., Matsuzaki, Y., Muraki, Y., Li, Z. N., and Nakamura, K. (2001). Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J. Gen. Virol. 82, 2475-2484.
118. Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., Hawe, L. A., Leander, K. R., Martinez, D., Perry, H. C., Shiver, J. W., Montgomery, D. L., and Liu, M. A. (1993). Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749.
119. Ulmer, J. B., Fu, T. M., Deck, R. R., Fried-man,A., Guan,L.,DeWitt,C.,Liu, X., Wang, S., Liu, M. A., Donnelly, J. J., and Caulfield, M. J (1998). Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 72, 5648-5653.
120. Virelizier, J. L., Allison, A. C., Oxford, J. S., and Schild, G. C. (1977). Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. Nature 266, 52-54.
121. Wang, T. T., Tan, G. S., Hai, R., Pica, N., Ngai, L., Ekiert, D. C., Wilson, I. A., Garcia-Sastre, A., Moran, T. M., and Palese, P. (2010). Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U.S.A. 107, 18979-18984.
122. Wei,C. J., Boyington, J. C., McTamney, P. M., Kong,W. P.,Pearce,M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z. Y., and Nabel, G. J. (2010). Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064.
123. Whitley, R. J., and Monto, A. S. (2006). Seasonal and pandemic influenza preparedness: a global threat. J. Infect. Dis. 194(Suppl. 2), S65-S69.
124. Wraith,D.C.,Vessey,A.E., andAskonas, B. A. (1987). Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68(Pt 2), 433-440.
125. Wrammert, J., Koutsonanos, D., Li, G. M., Edupuganti, S., Sui, J., Morris-sey,M.,McCausland,M.,Skountzou, I., Hornig, M., Lipkin, W. I., Mehta, A., Razavi, B., Del Rio, C., Zheng, N. Y., Lee, J. H., Huang, M., Ali, Z., Kaur, K., Andrews, S., Amara, R. R., Wang, Y., Das, S. R., O'Donnell, C. D., Yewdell, J. W., Subbarao, K., Marasco, W. A., Mulligan, M. J., Compans, R., Ahmed, R., and Wilson, P. C. (2011). Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193.
126. Wrammert, J., Smith, K., Miller, J., Lan-gley, W. A., Kokko, K., Larsen, C., Zheng, N. Y., Mays, I., Garman, L., Helms, C., James, J., Air, G. M., Capra, J. D., Ahmed, R., and Wilson, P. C. (2008). Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671.
127. Xie, H., Jing, X., Li, X., Lin, Z., Plant, E., Zoueva, O., Yang, H., and Ye, Z. (2011). Immunogenic-ity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS ONE 6, e16650. doi:10.1371/jour-nal.pone.0016650
128. Xu, R., Ekiert, D. C., Krause, J. C., Hai, R., Crowe, J. E. Jr., and Wilson, I. A. (2010). Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357-360.
129. Yamane, N., Odagiri, T., Arikawa, J., and Ishida, N. (1981). Reversed single-radial-immunodiffusion test: the method for the assay of the antibody to influenza A nucleo-protein. Tohoku J. Exp. Med. 133, 245-255.
130. Yewdell, J. W., Frank, E., and Gerhard, W. (1981). Expression of influenza A virus antigens on the surface of infected P815 cells. J. Immunol. 126, 1814-1819.
131. Yu,X.,Tsibane,T.,McGraw,P.A.,House, F. S., Keefer, C. J., Hicar, M. D., Tumpey, T. M., Pappas, C., Perrone, L. A., Martinez, O., Stevens, J., Wilson, I. A., Aguilar, P. V., Altschuler, E. L., Basler, C. F., and Crowe, J. E. Jr. (2008). Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455, 532-536.
132. Zharikova,D., Mozdzanowska,K.,Feng, J., Zhang, M., and Gerhard, W. (2005). Influenza type A virus escape mutants emerge in vivo in the pres-enceof antibodiestothe ectodomain of matrix protein 2. J. Virol. 79, 6644-6654.
133. Zheng, B., Zhang, Y., He, H., Mari-nova, E., Switzer, K., Wansley, D., Mbawuike, I., and Han, S. (2007). Rectification of age-associated deficiency in cytotoxic T cell response to influenza a virus by immunization with immune complexes. J. Immunol. 179, 6153-6159.